T cell-depleted allogeneic bone marrow transplantation as post remission therapy for acute myelogenous leukaemia
The paper by EB Papadopoulos and colleagues 1 adds support to our earlier observations published some 5 years ago. 2 However, the American programme differs in three significant ways.
Firstly, there is marked contrast in the complexity of the two approaches. Specifically, their technique for T cell depletion involves exposure of the bone marrow to sequential soybean lectin agglutination and sheep red blood rosette depletion. In contrast, the Constantiaberg Medi-Clinic method is simplicity itself, where 20 mg of CAMPATH 1G was added to the bag in vitro, gently agitated at room temperature for 30 min, and everything infused without further manipulation.
Secondly, the New York group emphasised that rejection prophylaxis and graft-versus-host disease are risk factors in their hands. Therefore, they add antithymocyte globulin and methylprednisolone in anticipation of graft failure. Since we have not seen this complication no such intervention is needed and the patients are spared significant additional costs and potential side-effects. Thirdly, with 20 AML patients transplanted with marrow as the source of haematopoietic stem cells and the longest follow-up of 8 years with a median of 5 years, neither acute nor chronic graft-versus-host disease (GVHD) has been seen. Similarly, cytomegaloviral infection was absent from our original experience, 2 but occurred in one graft at 3 months when prophylaxis was discontinued, and the patient died from pneumonitis. Since the first report, four individuals have relapsed: two died at 3 months, one at a year and one at 7 years. Two others, one transplanted in relapse and one who developed disseminated varicella zoster, have died. The remaining patients are well and continue in complete remission.
In the last 4 years this programme has been modified by using mononuclear cells recovered from the peripheral blood (PBSC) by apheresis technology. 3 Furthermore, the rat monoclonal CAMPATH 1G (n = 11: median follow-up 20 months) has been discontinued and substituted with the humanised version 1H (n = 33: median follow-up 9 months). 4 Accepting that numbers are small and followup short, these 44 patients, transplanted with a variety of haematologic disorders, have been characterized by uniform engraftment after the standardised preparative programme. 3 There has been a striking reduction in time to achieve corresponding peripheral blood count values. Thus, for 0.5 and 1.0 × 10 9 /l circulating granulocytes the values after marrow infusion were 18 (9-34) and 28 (10-59) days and for platelets of 25 and 50 × 10 9 /l, 17 (5-32) and 27 (13-127) days. In contrast, the corresponding figures for disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
peripheral blood being 12 (12-40) and platelets 12 (12-42) and (12-51) days. This reduction of approximately 1 week markedly reduces costs for hospitalization, need for nephrotoxic antibiotics and transfusion of blood and platelets.
In the combined group (n = 44) there were eight patients with AML and, to date, none have relapsed. Among those whose PBSC were exposed to the now discontinued CAMPATH 1G, none developed CMV, while two had mild erythroderma.
With CAMPATH 1H, four have sero-converted to CMV and another four had a skin rash. Biopsy has failed to reveal any evidence of classic GVHD. Whether this is grade I cutaneous manifestation which is a forme frust due to the T cell depletion, as opposed to being virus or drug-related, is unproven.
The most notable observation parallels that of Dr Papadopoulos and associates in which the earlier experience, reported with marrow as the source of the graft, has a low relapse rate in patients with AML. Although it is too early to be sure of what will happen with peripheral blood stem cells a similar pattern appears to be emerging. Whilst commenting here primarily on acute myelogenous leukaemia, similarly excellent results have been obtained with idiopathic bone marrow failure, Fanconi anaemia, lymphomas, chronic myeloid leukaemia, and a small number of solid tumours. As originally pointed out, 2 we believe our data are consistent with GVHD not being an obligatory correlate with a separate graft-versus-leukaemia benefit that is associated with allogeneic haematopoietic stem and progenitor cell transplantation. It is our viewpoint that CAMPATH 1G, or preferably 1H, is an alternative to the American programme, and perhaps a rather simpler approach to achieving acceptably similar results.
These ongoing investigations, which are part of the larger activity of the Campath Users Group, 4 are shortly to be formally updated (Hale, unpublished), but we would take the stance that marrow no longer needs to be used, since an equally effective and considerably less expensive source of the required lymphohaematopoietic population can be derived from the peripheral blood using cell separator technology. Furthermore, we do not believe that it is justifiable to continue using unmodified marrow allografts, given the benefits that are evident from ex vivo manipulation, resulting in uniform engraftment, absence of acute and chronic graft-versus-host disease, and a surprisingly low incidence of viral infection and an acceptable leukaemic relapse rate in AML. Our current activities centre on documenting the patterns of immunologic reconstitution, since manipulation of total cell numbers and mononuclear subtype in the infused graft, as well as biologic immune response modulation, may further reduce erythroderma and post-transplant infectious episodes. This model using matched siblings is the basis for extending the identical practice to matched unrelated volunteer donor grafts.
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؉ blood cells in leukemia or lymphoma patients at high risk of GVHD Allogeneic blood cell transplantation (BCT) is a fascinating example of adoptive immunotherapy, in which the graftversus-leukemia (GVL) effect contributes to the cure of a proportion of leukemias and other malignancies. However, its applicability is limited by graft-versus-host disease (GVHD). T cell depletion is an efficient way to prevent, or reduce the incidence and severity of GVHD, although this efficacy is associated with a higher incidence of relapses and graft failures. A decade ago, complement-mediated cytotoxicity was widely used for T cell depletion of bone marrow grafts. The use of these techniques is now restricted by new regulations in cell therapy facilities, and modern biomedical devices are increasingly substituted: the prototypical examples are CD34 ϩ cell selection devices, that indirectly achieve a very efficient T cell depletion.
1,2 Other developments in medical technologies contribute to a renewed interest in T cell depletion: collection of allogeneic aphereses from mobilized healthy donors produces grafts that are enriched in hematopoietic progenitors and stem cells when compared with bone marrow grafts. 3, 4 Thus, the combination of allogeneic blood cells with CD34 ϩ cell selection offers an attractive strategy for T cell depletion, with the expectation that the risk of graft failure may be overcome by the reinfusion of large numbers of hematopoietic progenitors. In addition, because donor lymphocyte infusions are able to induce new remissions in patients who relapse after allogeneic transplantation, there is hope that prophylactic infusions of donor lymphocytes (such as cells collected in the so-called 'CD34 − fraction') may reduce the frequency of leukemic relapses following T cell-depleted allogeneic transplantation.
In two recent reports, 5,6 the most recent in this journal /kg, they report a full and rapid engraftment, the nearly total absence of GVHD and no increase in relapse rate.
Our own experience has produced less favorable results. Fourteen patients at risk of developing aGVHD (age у40 years: n = 11, or advanced disease: n = 9) were prepared after informed consent with cytoxan (120 mg/kg) and TBI (12 Gy in six fractions over 3 days) ( Table 1) . Three patients had an additional dose of melphalan, 140 mg/m 2 . GVHD prophylaxis consisted of cyclosporin A, methotrexate (MTX) (days 1, 3 and 6) and one dose of anti-thymocyte globulin (ATG) for the eight first patients. Because we observed that cell selection consistently resulted in the reinfusion of less than 0.1 × 10 6 CD3 ϩ cells/kg, GVHD prophylaxis was reduced (MTX only: n = 2) and eventually suppressed (n = 4). Donors were mobilized with rhG-CSF (Neupogen, Amgen, Thousand Oaks, CA, USA), 10 g/kg daily, for 5 days. Two patients received unselected cells, because of poor mobilization of their healthy sibling, and both patients died of GVHD. For the 12 other donors, a median number of 9.97 (5.2-26.2) CD34 ϩ cells/kg, and 333.1 (52.6-744.3) CD3 ϩ × 10 6 /kg were collected with a median of 2 (2-3) aphereses. CD34 ϩ cell selection was performed using the Isolex 300i biomedical device (Nexell, Irvine, CA, USA), according to the manufacturer's recommendations (immuno-magnetic method). A median of 4.6 × 10 6 adsorbed CD34 ϩ cells/kg (2.19-9.53), and of 0.17 × 10 6 CD3 ϩ cells/kg (0.04-0.67) were obtained after selection, and infused into the patients. The median loss of CD34 ϩ progenitors was 46.1% (68.6%-15.6%), and the median T cell depletion was 3.4 log (2.75-5.51).
The outcome for these high risk patients is uniformly poor: in addition to the two patients who received unselected cells, all 12 patients died at a median of 75 days after transplantation (9-520). One patient died on day 9 of bacterial sepsis. Four patients experienced graft failure: three of them did not show any evidence of engraftment, and one had a secondary graft rejection, coincidental with CMV disease and treatment with DHPG (all patients were checked twice weekly for CMV antigenemia, and preemptively treated); these observations were not associated with the lowest numbers of hematopoietic progenitors, or of infused CD3 ϩ cells. Four patients experienced grade II to IV aGVHD, which was the cause of death in three cases. The two patients who had grade IV aGVHD were 45 and 50 year old, were infused with 0.044 and 0.065 × 10 6 CD3 ϩ cells/kg, and did not receive any post-graft immunosuppression. Three patients relapsed at 31, 60 and 330 days post-
